Grants per year
Personal profile
Research Interests
The Paller lab studies the role of topically-applied, nanotherapy based gene therapy to treat skin disease, particularly diabetic ulcers, psoriasis, atopic dermatitis (eczema), skin cancer, and rare genetic skin problems. Her lab also focuses on unraveling the mechanism by which membrane-based glycosphingolipids modulate signaling, especially of the insulin-like growth factor-1 receptor (IGF-1R) and the epidermal growth factor receptor (EGFR)and studying the mechanism of the abnormal innervation in skin related to pain. Dr. Paller is the PI of Northwestern's Skin Disease Research Center, which includes 3 Cores dedicated to providing service to researchers of skin biology. As a pediatric dermatologist, Dr. Paller specializes in genetic (esp. ichthyoses and epidermolysis bullosa) and immune-mediated inflammatory (esp. atopic dermatitis, psoriasis and autoimmune disorders) in children. As director of pediatric dermatology clinical research, Dr. Paller has led almost 100 clinical trials. Her most recent translational research has: a) defined the immunophenotypes in early atopic dermatitis in children, paving the way for targeted therapy; b) discovered the immune dysregulation that may lead to inflamed skin in the ichthyoses, leading to a novel clinical trial with repurposed medication; and c) discovered evidence for an important role for ganglioside GM3 as an intermediate in the insulin resistance in diabetic skin and also in development of diabetic neuropathy.
Certifications and Licenses
Pediatric Dermatology | |
Pediatrics | |
Dermatology |
Training Experience
1981 | Residency, Northwestern University, McGaw Medical Center (Children’s Memorial Hospital) |
1983 | Residency, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
1984 | Postdoctoral Fellowship, University of North Carolina |
1984 | Fellowship, University of North Carolina School of Medicine |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Stanford University
… → 1978
Research interests keywords
- Biochemistry: Lipids
- Dermatology
- Diabetes
- Genetics
- Genomic Medicine/Personalized Medicine
- Signal Transduction
- Skin
- Skin Cancer
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Post Graduate Program in Cutaneous Biology
National Institute of Arthritis and Musculoskeletal and Skin Diseases
7/1/23 → 6/30/28
Project: Research project
-
Paller Subproject for Sampling and Sensing Technologies for Spatiotemporal Inflammation Monitoring within Instrumented Skin
7/1/23 → 6/30/25
Project: Research project
-
Cardiovascular Risk in Pediatric Psoriasis
Pediatric Dermatology Research Alliance, Inc
7/1/23 → 6/30/24
Project: Research project
-
A call for implementing augmented intelligence in pediatric dermatology
Issa, C. J., Reimer-Taschenbrecker, A. & Paller, A. S., May 1 2023, In: Pediatric dermatology. 40, 3, p. 584-586 3 p.Research output: Contribution to journal › Article › peer-review
-
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata
Mikhaylov, D., Glickman, J. W., Del Duca, E., Nia, J., Hashim, P., Singer, G. K., Posligua, A. L., Florek, A. G., Ibler, E., Hagstrom, E. L., Estrada, Y., Rangel, S. M., Colavincenzo, M., Paller, A. S. & Guttman-Yassky, E., Mar 2023, In: Archives of Dermatological Research. 315, 2, p. 181-189 9 p.Research output: Contribution to journal › Article › peer-review
12 Scopus citations -
Assessing pain catastrophizing and functional disability in pediatric epidermolysis bullosa patients
Rangu, S., Collins, J., García-Romero, M. T., Augsburger, B. D., Bruckner, A. L., Diaz, L. Z., Eichenfield, L. F., Faig, W., Gorell, E. S., Lefferdink, R., Lucky, A. W., Morel, K. D., Paller, A. S., Park, H., Pastrana-Arellano, E., Peoples, K., Wiss, K., Perman, M. J. & Castelo-Soccio, L., May 1 2023, In: Pediatric dermatology. 40, 3, p. 422-427 6 p.Research output: Contribution to journal › Article › peer-review
-
Biologics in the management of childhood atopic dermatitis
Butala, S. & Paller, A. S., Mar 2023, In: Journal of Allergy and Clinical Immunology. 151, 3, p. 681-685 5 p.Research output: Contribution to journal › Editorial › peer-review
Open Access -
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations
Butala, S., Castelo-Soccio, L., Seshadri, R., Simpson, E. L., O'Shea, J. J., Bieber, T. & Paller, A. S., May 2023, In: Journal of Allergy and Clinical Immunology: In Practice. 11, 5, p. 1361-1373 13 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations
Datasets
-
-
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Paller, A. (Creator), Flohr, C. (Creator), Eichenfield, L. (Creator), Weisman, J. (Creator), Soung, J. (Creator), Natalie, C. R. (Creator), Capriles, C. R. (Creator), Pierce, E. (Creator), Reifeis, S. (Creator), Lima, R. G. (Creator), Laquer, V. (Creator) & Weidinger, S. (Creator), Adis Journals, 2023
DOI: 10.6084/m9.figshare.22801229.v2, https://adisjournals.figshare.com/articles/media/Safety_and_Efficacy_of_Lebrikizumab_in_Adolescent_Patients_with_Moderate-to-Severe_Atopic_Dermatitis_A_52-Week_Open-Label_Phase_3_Study/22801229/2
Dataset
-
Additional file 1 of Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study
Murrell, D. F. (Contributor), Paller, A. (Creator), Bodemer, C. (Creator), Browning, J. (Creator), Nikolic, M. (Contributor), Barth, J. A. (Creator), Lagast, H. (Creator), Krusinska, E. (Creator) & Reha, A. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.12687185, https://springernature.figshare.com/articles/Additional_file_1_of_Wound_closure_in_epidermolysis_bullosa_data_from_the_vehicle_arm_of_the_phase_3_ESSENCE_Study/12687185
Dataset
-
Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
Paller, A. (Creator), Yosipovitch, G. (Creator), Weidinger, S. (Creator), DiBenedetti, D. (Creator), Whalley, D. (Creator), Gadkari, A. (Creator), Guillemin, I. (Creator), Zhang, H. (Creator), Eckert, L. (Creator), Chao, J. (Creator), Bansal, A. (Creator), Chuang, C. (Creator), Delevry, D. (Creator), Paller, A. (Creator) & Chao, J. (Creator), Adis Journals, 2022
DOI: 10.6084/m9.figshare.20655396.v1, https://adisjournals.figshare.com/articles/media/Development_Psychometric_Validation_and_Responder_Definition_of_Worst_Itch_Scale_in_Children_with_Severe_Atopic_Dermatitis/20655396/1
Dataset
-
Additional file 2 of Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)
Paller, A. (Creator), Browning, J. (Creator), Nikolic, M. (Contributor), Bodemer, C. (Creator), Murrell, D. F. (Contributor), Lenon, W. (Contributor), Krusinska, E. (Creator), Reha, A. (Creator), Lagast, H. (Creator) & Barth, J. A. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.12552536, https://springernature.figshare.com/articles/Additional_file_2_of_Efficacy_and_tolerability_of_the_investigational_topical_cream_SD-101_6_allantoin_in_patients_with_epidermolysis_bullosa_a_phase_3_randomized_double-blind_vehicle-controlled_trial_ESSENCE_study_/12552536
Dataset